Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
3.360
-0.160 (-4.55%)
At close: Aug 1, 2025, 4:00 PM
3.370
+0.010 (0.30%)
After-hours: Aug 1, 2025, 7:10 PM EDT

Company Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.

It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases.

It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins; and RLY-1013, a degrader of estrogen receptor alpha.

In addition, the company develops lirafugratinib (RLY-4008), a receptor tyrosine kinase for the treatment of cancer.

It has collaboration and license agreements with D. E.

Shaw Research, LLC to research certain biological targets through the use of D. E.

Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; Elevar Therapeutics, Inc. for the development and commercialization of RLY-4008; and Pfizer Inc. for the development of RLY-2608 in combination with fulvestrant and atirmociclib.

The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.

Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc.
Relay Therapeutics logo
CountryUnited States
Founded2015
IPO DateJul 16, 2020
IndustryBiotechnology
SectorHealthcare
Employees261
CEOSanjiv Patel

Contact Details

Address:
399 Binney Street, 2nd Floor
Cambridge, Massachusetts 02142
United States
Phone617 370 8837
Websiterelaytx.com

Stock Details

Ticker SymbolRLAY
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$20.00
CIK Code0001812364
CUSIP Number75943R102
ISIN NumberUS75943R1023
SIC Code2836

Key Executives

NamePosition
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBSChief Executive Officer, President and Director
Thomas CatinazzoChief Financial Officer
Brian R. Adams J.D.Chief Legal Officer and Secretary
Peter RahmerChief Corporate Development Officer
Dr. Donald A. Bergstrom M.D., Ph.D.President of Research and Development
Dorothee Kern Ph.D.Founder
Dr. David Elliot Shaw Ph.D.Founder
Matthew P. Jacobson Ph.D.Founder
Jim Watters Ph.D.Chief Scientific Officer
Dr. Mahesh Padval Ph.D.Chief Pharmaceutical Development Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 2025SCHEDULE 13G/AFiling
Jun 11, 20258-KCurrent Report
Jun 6, 20258-KCurrent Report
Jun 4, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 5, 202510-QQuarterly Report
May 5, 20258-KCurrent Report
Apr 30, 2025SCHEDULE 13G/AFiling
Apr 29, 2025144Filing
Apr 28, 2025144Filing